Effects of IZL-2003Ⅱ Immune Therapy System on lymphocyte immunofunction in advanced non-small-cell lung cancer patients after chemotherapy / 中国基层医药

ABSTRACT

Objective To study the effect of IZL-2003Ⅱ Immune Therapy System on lymphocyte immuno-function induced by chemotherapy in advanced non-small-cell lung cancer(NSCLC)patients.Methods 112 cases of advanced NSCLC patients were randomly divided into the two groups .The treatment group ( n=56 ) was given IZL-2003ⅡImmune Therapy System after chemotherapy for 6d as a couse and the control group ( n=56) was given chem-otherapy only.The peripheral blood routine and T lymphocyte subgroup (CD3+,CD4+, CD8+and CD4+/CD8+)activity of patients in both group were measured by flow cytometry 1 day before chemotherapy and the 8th day after chemothera-py.ResultsThere was difference between the treatment group and control group on the increasing rate of Leucocyte (P<0.05)the 8th day after treatment;After the 8th day,the expression levels of CD8+T cells was lower,but has no significant(P<0.05);The expression levels of CD3+,CD4+and the ratio of CD4+/CD8+were higher in the treatment group(P<0.05).The expression levels of CD3+T cells was lower,but has no significant(P<0.05);The expression levels of CD4+T cells and the ratio of CD 4+/CD8+were significantly lower after treatment in control group ( P<0.05);the expression levels of CD8+T cell was higher significantly in the control group (P<0.05).Conclusion IZL-2003ⅡImmune Therapy System can antagonize myelosuppression and elevated the immunologyical function of advanced NSCLC patients significantly .